Medical School · Year 2 · Renal · includes a quiz and discussion video

Lecture 13: Urinary Tract Infections

Unit 2.1: Renal System

Learning Objectives

By the end of this lecture, students will be able to:

1. Classify urinary tract infections by anatomical location and complexity
2. Describe the pathophysiology of UTI and host defense mechanisms
3. Identify the common pathogens causing UTIs
4. Describe the clinical presentation and diagnosis of UTIs
5. Explain the treatment strategies for different types of UTIs
6. Describe prevention strategies for recurrent UTIs

Classification and Definitions

Urinary tract infections encompass a spectrum of conditions ranging from asymptomatic colonization to life-threatening sepsis. Proper classification guides appropriate evaluation, treatment intensity, and follow-up. The anatomical site of infection, presence of complicating factors, and patient characteristics all influence management decisions.

Anatomical classification divides UTIs by location within the urinary system. Cystitis refers to infection confined to the bladder, presenting with lower urinary tract symptoms. Urethritis involves the urethra and is frequently associated with sexually transmitted infections. Pyelonephritis denotes kidney infection with parenchymal involvement, producing systemic symptoms. Prostatitis affects the prostate gland in men and may be acute or chronic.

The distinction between uncomplicated and complicated UTI carries significant clinical implications. Uncomplicated UTI occurs in a healthy, non-pregnant woman with an anatomically and functionally normal urinary tract. These infections typically respond promptly to short-course antibiotic therapy. Complicated UTI occurs when factors are present that increase the likelihood of treatment failure or serious complications. These factors include anatomic abnormalities (obstruction, stones, stents), functional abnormalities (neurogenic bladder, vesicoureteral reflux), foreign bodies (indwelling catheters), host factors (male sex, diabetes, immunocompromise), and pregnancy.

Recurrent UTI is defined as two or more infections within six months or three or more within twelve months. Recurrence may represent relapse (same organism, suggesting persistent source) or reinfection (different organism or same organism after documented clearance). Catheter-associated UTI (CAUTI) develops in patients with indwelling urinary catheters in place for at least 48 hours. Asymptomatic bacteriuria (ASB) describes the presence of bacteria in appropriately collected urine at significant concentrations without symptoms of UTI.

<image>Panel A: Anatomical classification on urinary tract diagram showing urethritis (urethra), cystitis (bladder), pyelonephritis (kidney parenchyma), and prostatitis (prostate in male anatomy). Panel B: Uncomplicated versus complicated UTI distinction with uncomplicated in a healthy non-pregnant woman with normal anatomy versus complicated involving obstruction, catheter, diabetes, male sex, immunocompromise, or pregnancy. Panel C: Recurrent UTI defined as 2 or more infections in 6 months or 3 or more in 12 months, distinguished as relapse (same organism, persistent source) versus reinfection (different organism or documented clearance). Panel D: CAUTI defined as infection with indwelling catheter for at least 48 hours with biofilm illustration, and asymptomatic bacteriuria showing bacteria in urine without UTI symptoms.</image>

Pathophysiology

The ascending route accounts for the vast majority of urinary tract infections. Bacteria from the periurethral region and distal urethra ascend through the urethra to colonize the bladder. In some cases, particularly with vesicoureteral reflux or anatomic abnormalities, bacteria continue ascending through the ureters to reach the kidney. This pathway explains the markedly higher UTI incidence in women, whose shorter urethras provide less barrier to ascending infection. Hematogenous spread to the kidney occurs rarely, typically with Staphylococcus aureus bacteremia seeding the kidney from a distant focus. Direct extension from adjacent infected structures represents an uncommon route.

Multiple host defense mechanisms normally protect against UTI. Urine flow provides mechanical washout, clearing bacteria before they can establish infection—urinary stasis from any cause therefore increases UTI risk. Low urine pH and high urea concentration create an inhospitable environment for bacterial growth. Tamm-Horsfall protein (uromodulin) secreted by the thick ascending limb binds bacterial fimbriae, preventing attachment to uroepithelium. The glycosaminoglycan layer coating the bladder epithelium provides a physical barrier. Secretory IgA provides mucosal immunity. In women, normal vaginal flora (lactobacilli) maintain an acidic pH that inhibits uropathogen colonization.

Bacterial virulence factors enable uropathogens to overcome host defenses. P fimbriae (pyelonephritis-associated pili) bind to glycolipid receptors on uroepithelial cells, facilitating attachment and ascending infection to the kidney. Type 1 fimbriae bind to mannose residues on bladder epithelium, enabling bladder colonization. Flagella provide motility for ascending through the urinary tract. Hemolysins damage host cells and release iron for bacterial metabolism. Capsular polysaccharides enable immune evasion. Urease, produced by Proteus and certain other species, generates ammonia that alkalinizes urine and promotes struvite stone formation.

<image>Panel A: Routes of infection showing ascending route (primary) with step-by-step progression from periurethra to bladder to ureter to kidney, hematogenous route (rare, S. aureus bacteremia), and direct extension (uncommon). Panel B: Host defenses showing urine flow providing mechanical washout, acidic pH and high urea concentration inhibiting bacteria, Tamm-Horsfall protein binding bacterial fimbriae, GAG layer on bladder epithelium, and secretory IgA. Panel C: Female-specific defenses and vulnerability showing vaginal lactobacilli maintaining acidic pH that inhibits uropathogen colonization, and shorter urethra explaining higher UTI incidence in women. Panel D: E. coli virulence factors showing P fimbriae (binding renal epithelium, enabling pyelonephritis), Type 1 fimbriae (bladder binding), flagella (ascending motility), hemolysin (cell damage and iron release), capsule (immune evasion), and urease in other species.</image>

Microbiology

Escherichia coli dominates as the causative organism in urinary tract infections, responsible for 80-90% of uncomplicated community-acquired cases. Uropathogenic E. coli (UPEC) strains possess specific virulence factors including P fimbriae, type 1 fimbriae, and hemolysins that distinguish them from non-pathogenic intestinal E. coli. The predominance of E. coli reflects its adaptation to the periurethral environment and its arsenal of uroepithelial adherence mechanisms.

Staphylococcus saprophyticus represents the second most common pathogen in uncomplicated UTI, particularly in sexually active young women, accounting for 10-15% of cases in this population. This organism adheres effectively to uroepithelial cells and produces urease. In complicated UTI settings, the microbiologic spectrum broadens. Proteus mirabilis possesses potent urease activity, producing ammonia that alkalinizes urine and promotes struvite stone formation; its "swarming" motility on agar plates is characteristic. Klebsiella species are more common in diabetics and complicated infections. Enterococcus species, inherently resistant to cephalosporins, emerge in complicated UTI and healthcare settings. Pseudomonas aeruginosa predominates in catheter-associated infections and nosocomial UTI, with intrinsic resistance to many antibiotics.

Sterile pyuria—white blood cells in urine without bacterial growth on standard culture—warrants consideration of alternative diagnoses. Prior antibiotic therapy may suppress bacterial growth. Fastidious organisms including Chlamydia trachomatis and Ureaplasma urealyticum cause urethritis but do not grow on standard urine culture. Genitourinary tuberculosis classically produces sterile pyuria with persistent symptoms. Acute interstitial nephritis causes pyuria through inflammatory rather than infectious mechanisms. Renal stones may produce pyuria without infection. Foreign bodies including ureteral stents can cause sterile pyuria.

<image>Panel A: Organism distribution showing E. coli dominant at 80-90% in uncomplicated UTI (UPEC strains with specific virulence factors) and S. saprophyticus at 10-15% in sexually active young women. Panel B: Complicated UTI organisms showing Proteus mirabilis (urease activity, struvite stones, swarming motility), Klebsiella (more common in diabetics), Enterococcus (inherent cephalosporin resistance), and Pseudomonas aeruginosa (catheter-associated and nosocomial, intrinsic resistance). Panel C: Organism characteristics showing E. coli P fimbriae enabling pyelonephritis, S. saprophyticus urease and uroepithelial adherence, and Proteus swarming motility on agar plates. Panel D: Sterile pyuria causes including prior antibiotics suppressing growth, fastidious organisms (Chlamydia, Ureaplasma), genitourinary tuberculosis (acid-fast bacilli), acute interstitial nephritis, renal stones, and foreign bodies such as ureteral stents.</image>

Uncomplicated Cystitis

Acute uncomplicated cystitis affects approximately 50% of women at least once during their lifetime, making it among the most common infectious diseases encountered in clinical practice. Sexual activity represents a major risk factor, with the historical term "honeymoon cystitis" reflecting this association. Spermicide and diaphragm use alter vaginal flora in ways that promote uropathogen colonization. Recurrence is common, with 25-30% of women experiencing another episode within six months.

The clinical presentation of uncomplicated cystitis features lower urinary tract symptoms without systemic manifestations. Dysuria, often described as burning or stinging with urination, is the most common symptom. Urinary frequency involves frequent voiding of small volumes. Urgency reflects bladder irritation causing a compelling need to void. Suprapubic discomfort or pressure may be present. Hematuria, when present, can be alarming to patients but commonly accompanies cystitis. Critically, fever is absent in uncomplicated cystitis—its presence suggests upper tract involvement (pyelonephritis) or complicated infection.

Diagnosis of uncomplicated cystitis in a woman with typical symptoms often proceeds empirically without laboratory confirmation. When urinalysis is performed, pyuria (>10 white blood cells per high-power field) supports the diagnosis. Leukocyte esterase on dipstick detects pyuria. Nitrites, produced by bacterial reduction of urinary nitrates, indicate bacteriuria but are insensitive because some organisms (Enterococcus, Pseudomonas) lack nitrate reductase. Urine culture is not routinely required for uncomplicated cystitis but should be obtained if the diagnosis is uncertain, symptoms are atypical, or the patient has recently received antibiotics.

Treatment of uncomplicated cystitis involves short-course antibiotic therapy. Nitrofurantoin for 5 days represents preferred first-line therapy, providing excellent coverage of common uropathogens with minimal effect on intestinal flora and limited promotion of resistance. Trimethoprim-sulfamethoxazole for 3 days remains effective where local resistance rates remain below 20%. Fosfomycin as a single-dose regimen offers convenience but may be less effective. Fluoroquinolones should be reserved for complicated infections given concerns about collateral effects including tendinopathy, aortic aneurysm, and resistance promotion.

<image>Panel A: Epidemiology showing 50% lifetime prevalence in women, risk factors including sexual activity and spermicide/diaphragm use, and 25-30% recurrence at 6 months. Panel B: Clinical features showing dysuria (burning with urination), urinary frequency and urgency, suprapubic discomfort, possible hematuria, and critically the absence of fever distinguishing from pyelonephritis. Panel C: Diagnosis showing urinalysis with pyuria (greater than 10 WBC/hpf), dipstick with leukocyte esterase (detects pyuria) and nitrites (insensitive as some organisms lack nitrate reductase), and urine culture not routinely needed but indicated for uncertain or atypical cases. Panel D: Treatment showing first-line nitrofurantoin for 5 days (preferred), TMP-SMX for 3 days (if local resistance below 20%), fosfomycin single dose (convenient), and fluoroquinolones reserved for complicated infections only.</image>

Pyelonephritis

Acute pyelonephritis represents bacterial infection of the renal parenchyma, a more serious condition than cystitis with potential for significant morbidity. Infection typically ascends from the bladder to the kidney, though vesicoureteral reflux facilitates upper tract involvement. The resulting inflammatory response produces systemic symptoms that distinguish pyelonephritis from lower tract infection.

Clinical presentation includes fever, often high (>38°C or 100.4°F), along with chills and rigors that suggest bacteremia. Flank pain with costovertebral angle tenderness on examination reflects renal capsular inflammation. Nausea and vomiting commonly accompany the systemic illness. Lower urinary tract symptoms (dysuria, frequency, urgency) may be present but are not universal, as some patients present primarily with fever and flank pain.

Diagnosis requires urinalysis showing pyuria, with white blood cell casts being pathognomonic for pyelonephritis when present (though their absence does not exclude the diagnosis). Urine culture should always be obtained to identify the organism and guide therapy. Blood cultures are appropriate in patients requiring hospitalization or with severe sepsis, as bacteremia occurs in 20-30% of pyelonephritis cases. Imaging is not routinely required but should be obtained if the patient fails to improve within 48-72 hours of appropriate therapy, raising concern for abscess, obstruction, or other complications.

Classification into uncomplicated and complicated pyelonephritis guides management intensity. Uncomplicated pyelonephritis occurs in a healthy, non-pregnant woman without anatomic or functional urinary tract abnormalities—many such patients can be managed as outpatients. Complicated pyelonephritis occurs with risk factors for treatment failure or serious complications, including anatomic obstruction, indwelling catheter or stent, male sex, diabetes, immunocompromise, pregnancy, or recent instrumentation.

Indications for hospitalization include inability to tolerate oral intake (requiring IV antibiotics), severe sepsis with hemodynamic instability, suspected obstruction requiring drainage, pregnancy (higher complication risk), and diagnostic uncertainty requiring workup.

<image>Panel A: Clinical presentation showing high fever (greater than 38 degrees C), chills and rigors suggesting bacteremia, flank pain with CVA tenderness, nausea and vomiting, and lower tract symptoms that may or may not be present. Panel B: Diagnosis showing urinalysis with pyuria and WBC casts (pathognomonic when present), urine culture (always obtain), blood cultures if severe or hospitalized (20-30% bacteremia rate), and imaging with CT if no improvement at 48-72 hours to evaluate for abscess or obstruction. Panel C: Uncomplicated versus complicated pyelonephritis with uncomplicated in a healthy non-pregnant woman suitable for outpatient management versus complicated involving obstruction, catheter, male sex, diabetes, immunocompromise, or pregnancy. Panel D: Hospitalization indications including inability to tolerate oral intake, severe sepsis with hemodynamic instability, suspected obstruction requiring drainage, pregnancy, and diagnostic uncertainty.</image>

Pyelonephritis Treatment

Outpatient management of uncomplicated pyelonephritis is appropriate for patients who can tolerate oral intake, have no severe sepsis, and have reliable follow-up. Fluoroquinolones (ciprofloxacin or levofloxacin) for 5-7 days provide excellent renal penetration and coverage of uropathogens, representing first-line outpatient therapy. Trimethoprim-sulfamethoxazole for 14 days serves as an alternative when fluoroquinolone resistance is present or contraindications exist. An initial intravenous antibiotic dose (ceftriaxone or an aminoglycoside) followed by oral therapy improves early response and is often administered in the emergency department or clinic before discharge.

Inpatient treatment is required for patients unable to take oral medications, those with severe sepsis or septic shock, suspected urinary tract obstruction, or complicated host factors. Intravenous fluoroquinolones, ceftriaxone, or piperacillin-tazobactam provide appropriate initial empiric coverage. Ampicillin plus an aminoglycoside provides enterococcal coverage when this organism is suspected based on Gram stain or prior culture results. Therapy is narrowed based on culture and sensitivity results once available. Transition to oral therapy occurs when the patient demonstrates clinical improvement, typically within 48-72 hours.

Treatment duration for uncomplicated pyelonephritis ranges from 5-7 days for fluoroquinolone regimens to 10-14 days for other agents. Complicated pyelonephritis typically requires 10-14 days of therapy, though longer courses may be needed for abscesses or persistent infection.

Treatment failure, defined as persistent fever and symptoms after 48-72 hours of appropriate therapy, warrants evaluation for complications. Resistant organisms may require antibiotic adjustment based on culture results. Abscess formation requires CT imaging and may need percutaneous or surgical drainage. Urinary tract obstruction must be relieved by ureteral stent or percutaneous nephrostomy. Structural abnormalities may require urologic evaluation and intervention.

<image>Panel A: Outpatient treatment for uncomplicated pyelonephritis showing fluoroquinolone (ciprofloxacin or levofloxacin) for 5-7 days as preferred, TMP-SMX for 14 days as alternative, and optional initial IV dose (ceftriaxone or aminoglycoside) in the emergency department. Panel B: Inpatient treatment for complicated or severe cases showing IV fluoroquinolone, ceftriaxone, or piperacillin-tazobactam, with ampicillin plus aminoglycoside if Enterococcus suspected, narrowing based on culture and switching to oral when improved. Panel C: Treatment duration showing uncomplicated 5-7 days for fluoroquinolone or 10-14 days for other agents, and complicated 10-14 days with longer courses for abscesses. Panel D: Treatment failure pathway at 48-72 hours showing evaluation for resistant organisms (adjust antibiotics per culture), CT imaging for abscess (may need percutaneous or surgical drainage), and relief of urinary obstruction (stent or nephrostomy).</image>

Complicated UTI and CAUTI

Complicated urinary tract infection encompasses infections occurring in patients with factors that increase the risk of treatment failure, ascending infection, or serious complications. Structural risk factors include obstruction (stones, strictures, tumors), indwelling foreign bodies (catheters, stents), and anatomic abnormalities (diverticula, fistulae). Functional abnormalities include neurogenic bladder, vesicoureteral reflux, and incomplete emptying from any cause. Host factors conferring complicated status include male sex, diabetes mellitus, immunocompromise (transplant recipients, HIV, chemotherapy), and pregnancy.

Treatment principles for complicated UTI differ from uncomplicated infection. Broader-spectrum empiric coverage is appropriate, targeting not only E. coli but also Enterococcus, Pseudomonas, and resistant Gram-negative organisms. Fluoroquinolones, ceftriaxone, or piperacillin-tazobactam provide appropriate initial therapy pending culture results. Longer treatment duration of 7-14 days is typically required. Addressing the underlying complicating factor is essential—removing or exchanging catheters, draining obstructions, and optimizing diabetes control. Urine culture should always be obtained to guide therapy.

Catheter-associated urinary tract infection (CAUTI) represents the most common healthcare-associated infection, accounting for 40% of hospital-acquired infections. The definition requires symptoms attributable to UTI (fever, suprapubic tenderness, costovertebral angle pain, or tenderness) in a patient with an indwelling catheter in place for at least 48 hours, plus urine culture growing at least 10³ colony-forming units per milliliter. The distinction from asymptomatic catheter-associated bacteriuria (which should not be treated) is crucial.

Catheter biofilms provide the pathophysiologic basis for CAUTI. Bacteria adhere to the catheter surface within hours of insertion and form biofilm communities protected from antibiotics and host defenses. Risk increases approximately 5% per day of catheterization, making duration the single most important risk factor.

CAUTI management begins with catheter removal or exchange, as antibiotics cannot penetrate established biofilms. Culture should be obtained from the new catheter to identify the causative organism. Treatment is guided by culture results, with duration of 7-14 days depending on symptom resolution. Prevention strategies focus on avoiding unnecessary catheterization, removing catheters as soon as possible, using alternatives when feasible (intermittent catheterization, condom catheters), and maintaining closed drainage systems.

<image>Panel A: Complicated UTI risk factors categorized as structural (stone obstruction, catheter or stent, anatomic abnormalities), functional (neurogenic bladder, vesicoureteral reflux), and host factors (male sex, diabetes, immunocompromise, pregnancy). Panel B: Complicated UTI treatment principles showing broader-spectrum empiric coverage (E. coli plus Enterococcus, Pseudomonas), longer duration (7-14 days), addressing the underlying complicating factor, and always obtaining urine culture. Panel C: CAUTI definition (symptoms plus catheter in place 48 or more hours plus culture at least 10 to the third CFU/mL), biofilm pathophysiology (cross-section showing bacterial biofilm layers on catheter surface), and risk increasing approximately 5% per day of catheterization. Panel D: CAUTI management showing catheter removal or exchange (antibiotics cannot penetrate established biofilms), culture from new catheter, treatment for 7-14 days, and prevention checklist (avoid unnecessary catheters, remove ASAP, use alternatives, maintain closed drainage).</image>

Special Populations

Pregnancy confers increased risk of pyelonephritis complications including preterm labor and low birth weight. Physiologic changes including ureteral dilation and relative urinary stasis promote ascending infection. Uniquely, asymptomatic bacteriuria should be screened for and treated during pregnancy to prevent progression to pyelonephritis—routine screening occurs at the first prenatal visit, and positive cultures are treated even without symptoms.

Antibiotic selection in pregnancy requires attention to fetal safety. Nitrofurantoin is generally safe but should be avoided near term due to theoretical risk of neonatal hemolysis. Cephalosporins (cephalexin) are safe throughout pregnancy. Amoxicillin-clavulanate is safe. Fosfomycin is safe for single-dose treatment. Trimethoprim-sulfamethoxazole should be avoided in the first trimester (folate antagonism) and near term (kernicterus risk). Fluoroquinolones are contraindicated due to cartilage toxicity.

UTI in men is uncommon in young adults and should prompt consideration of sexually transmitted infection. In older men, UTI almost always represents complicated infection, often related to prostatic enlargement or prior instrumentation. Evaluation should consider prostatitis, which presents with similar symptoms but requires longer antibiotic courses (4-6 weeks for acute bacterial prostatitis) with agents that penetrate prostatic tissue (fluoroquinolones, trimethoprim-sulfamethoxazole). Treatment duration for cystitis or pyelonephritis in men is typically 7-14 days.

Pediatric UTI raises concerns about vesicoureteral reflux and renal scarring. Young children may present with nonspecific symptoms including fever, irritability, and poor feeding. Post-UTI imaging with renal ultrasound is often performed to evaluate for structural abnormalities, and voiding cystourethrogram may be indicated to diagnose reflux, particularly with recurrent UTI or abnormal ultrasound.

UTI in elderly patients often presents atypically, with confusion, falls, or new incontinence rather than classic urinary symptoms. However, this creates diagnostic challenges because bacteriuria is extremely common in older adults, particularly those in nursing homes. Mental status changes in elderly patients with bacteriuria do not necessarily indicate UTI—thorough evaluation for other causes is essential to avoid antibiotic overuse.

<image>Panel A: Pregnancy showing increased pyelonephritis risk (preterm labor, low birth weight), screening and treating ASB at first prenatal visit, safe antibiotics (nitrofurantoin with near-term caution, cephalexin, amoxicillin-clavulanate, fosfomycin), and contraindicated antibiotics (TMP-SMX in first trimester and near term, fluoroquinolones). Panel B: Men showing UTI uncommon in young adults (consider STI), complicated in older men (prostatic enlargement), prostatitis requiring longer courses (4-6 weeks) with prostatic-penetrating agents, and 7-14 day treatment for cystitis or pyelonephritis. Panel C: Pediatric UTI showing vesicoureteral reflux concern, renal scarring risk, nonspecific presentation in young children (fever, irritability, poor feeding), and post-UTI imaging with renal ultrasound and VCUG for recurrent or abnormal cases. Panel D: Elderly showing atypical presentation (confusion, falls, new incontinence), extremely common bacteriuria (particularly in nursing homes), and the critical warning to evaluate other causes before attributing mental status changes to UTI.</image>

Asymptomatic Bacteriuria

Asymptomatic bacteriuria is defined as the presence of bacteria in properly collected urine at significant concentrations in a patient without symptoms of urinary tract infection. The definition requires at least 10⁵ colony-forming units per milliliter in a midstream clean-catch specimen, with two consecutive positive cultures required for women but only one for men. The distinction between ASB and symptomatic UTI is clinically important because management differs fundamentally.

Only two situations warrant screening for and treatment of asymptomatic bacteriuria. Pregnancy represents the primary indication, as treatment of ASB reduces the risk of pyelonephritis by 75-80% and prevents associated adverse pregnancy outcomes. Screening at the first prenatal visit is standard of care. Prior to urologic procedures, particularly those involving mucosal disruption (transurethral resection, prostate biopsy), treatment of ASB reduces postoperative infectious complications.

In nearly all other situations, asymptomatic bacteriuria should not be treated. Evidence consistently shows no benefit from treating ASB in elderly patients, those with diabetes, persons with spinal cord injury, patients with indwelling catheters, or nursing home residents. Negative studies demonstrate that treatment neither improves outcomes nor reduces symptomatic infection rates in these populations.

The harms of treating asymptomatic bacteriuria are substantial. Antibiotic exposure creates selection pressure that promotes development of resistant organisms, both in the individual patient and in the broader community. Adverse drug reactions, including C. difficile colitis, allergic reactions, and drug interactions, occur without offsetting benefit. Healthcare costs increase unnecessarily. The fundamental principle is that bacteriuria represents colonization, not infection, unless accompanied by symptoms—and colonization does not require treatment.

<image>Panel A: ASB definition showing at least 10 to the fifth CFU/mL in midstream specimen, two consecutive positive cultures required for women and one for men, with no UTI symptoms present. Panel B: Indications to treat showing pregnancy (reduces pyelonephritis risk by 75-80%, standard prenatal screening at first visit) and prior to urologic procedures involving mucosal disruption (reduces postoperative infection). Panel C: Populations where treatment provides no benefit and should not be given, including elderly, diabetics, persons with spinal cord injury, patients with indwelling catheters, and nursing home residents. Panel D: Harms of unnecessary treatment showing antibiotic resistance promotion, adverse effects (C. difficile colitis, allergic reactions, drug interactions), unnecessary healthcare costs, and the central principle that bacteriuria without symptoms represents colonization rather than infection.</image>

Prevention of Recurrent UTI

Behavioral measures represent first-line prevention for recurrent UTI, though evidence supporting individual interventions varies in strength. Adequate hydration dilutes urine and promotes frequent voiding that flushes bacteria from the bladder—a recent randomized trial demonstrated that increasing fluid intake by 1.5 liters daily reduced UTI recurrence by approximately 50% in premenopausal women. Post-coital voiding, while lacking rigorous evidence, is reasonable and commonly recommended. Avoidance of spermicides, which disrupt protective vaginal flora, may reduce recurrence in users of this contraceptive method. The traditional advice to wipe front-to-back is universally recommended despite limited direct evidence.

Non-antibiotic prophylaxis options provide alternatives to chronic antibiotic use. Cranberry products have been extensively studied with conflicting results—modest benefit is possible, but effect sizes are small and the optimal formulation unclear. Vaginal estrogen represents an effective intervention in postmenopausal women, restoring vaginal lactobacilli, lowering vaginal pH, and reducing uropathogen colonization. Meta-analyses demonstrate significant reduction in UTI recurrence. D-mannose, a simple sugar that competitively inhibits type 1 fimbrial binding to bladder epithelium, has some supporting evidence. Probiotics (oral or vaginal lactobacillus preparations) show limited evidence but theoretical benefit.

Antibiotic prophylaxis effectively reduces recurrent UTI but should be reserved for patients with frequent recurrence despite behavioral modifications. Continuous prophylaxis involves low-dose antibiotics taken nightly (nitrofurantoin 50-100 mg or trimethoprim-sulfamethoxazole half-strength tablet). Post-coital prophylaxis involves a single antibiotic dose after sexual intercourse for women whose UTIs correlate with sexual activity. Self-start (patient-initiated) therapy allows patients to begin a short course of antibiotics at the first sign of symptoms, reducing healthcare visits while ensuring prompt treatment. Prophylaxis is typically continued for 6-12 months before reassessment, as recurrence patterns may change over time.

<image>Panel A: Behavioral measures showing increased hydration (1.5 L/day additional fluid reducing recurrence by approximately 50%), post-coital voiding (reasonable though limited evidence), avoidance of spermicides, and front-to-back wiping. Panel B: Non-antibiotic prophylaxis showing cranberry products (conflicting evidence, possible modest benefit), vaginal estrogen for postmenopausal women (restores lactobacilli and lowers vaginal pH), D-mannose (competitively inhibits Type 1 fimbrial binding), and probiotics (limited evidence). Panel C: Antibiotic prophylaxis strategies showing continuous low-dose nightly (nitrofurantoin 50-100 mg or TMP-SMX half-strength), post-coital single dose for intercourse-related UTIs, and self-start patient-initiated therapy at first symptom onset. Panel D: Indications for antibiotic prophylaxis (3 or more UTIs per year, failed non-antibiotic measures, significant quality of life impact), duration of 6-12 months before reassessment, and acknowledgment that recurrence patterns may change over time.</image>

Summary

Urinary tract infections are classified anatomically (cystitis, pyelonephritis) and by complexity (uncomplicated versus complicated). Escherichia coli causes 80-90% of uncomplicated UTI, with UPEC strains possessing P fimbriae and other virulence factors. Staphylococcus saprophyticus is the second most common pathogen in sexually active young women. Complicated UTI involves a broader spectrum including Proteus, Klebsiella, Enterococcus, and Pseudomonas.

Uncomplicated cystitis presents with dysuria, frequency, and urgency without fever. First-line treatment is nitrofurantoin for 5 days or trimethoprim-sulfamethoxazole for 3 days. Pyelonephritis presents with fever, flank pain, and CVA tenderness; WBC casts are pathognomonic. Treatment with fluoroquinolones or ceftriaxone ranges from 5-7 days (outpatient fluoroquinolone) to 10-14 days (complicated).

Complicated UTI requires broader-spectrum therapy, longer duration, and attention to underlying complicating factors. CAUTI management centers on catheter removal, with prevention focusing on avoiding unnecessary catheterization.

Asymptomatic bacteriuria should only be treated in pregnancy and prior to urologic procedures—treatment in other populations provides no benefit and causes harm through resistance selection and adverse effects. Prevention of recurrent UTI includes behavioral measures, non-antibiotic options (vaginal estrogen in postmenopausal women), and antibiotic prophylaxis when necessary.

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown